Disease · MONDO_0018312

histoplasmosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. histoplasmosis. Diseases, record MONDO_0018312. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018312

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: histoplasmosis; Open Targets
Open Targets ID: MONDO_0018312; Open Targets
Other names: Histoplasma caused disease or disorder, Histoplasma disease or disorder, Histoplasma infectious disease, Reticuloendothelial hyperplasia, darling disease, reticuloendotheliosis; Open Targets
Disease Ontology: DOID:1731; Disease Ontology
MeSH: D006660; MeSH
NCI Thesaurus: C77201; NCI Thesaurus
Orphanet: ORPHA:390; Orphanet
Highest stage of its drugs: Approval, for 2 of its 4 drugs, from DailyMed and PMDA; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ITRACONAZOLE	CHEMBL64391	Small molecule	Approval	PMDA	4	3	3	Drugs and targets
AMPHOTERICIN B	CHEMBL267345	Small molecule	Approval	DailyMed	3	2	1	Drugs and targets
POSACONAZOLE	CHEMBL1397	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUCONAZOLE	CHEMBL106	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03572049	Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole	Phase 2/3	88	2022-10-06	Invasive Fungal Infections	ITRACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT07261150	Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)	Phase 3	664		Histoplasmosis	POSACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00000627	Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome	Not applicable	90		HIV Infections, Histoplasmosis	FLUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00004808	Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis	Phase 2	78		Histoplasmosis, Sporotrichosis, Blastomycosis	FLUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00002159	A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis	Phase 3	60		HIV Infections, Histoplasmosis, Blastomycosis	AMPHOTERICIN B, ITRACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00004811	Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis	Phase 1/2	7		Histoplasmosis, Sporotrichosis, Blastomycosis	ITRACONAZOLE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
SUBA Itraconazole vs Conventional Itraconazole: deaths from any cause	1 of 42	0 of 46	88	NCT03572049	Trial comparisons
SUBA Itraconazole vs Conventional Itraconazole: serious adverse events	4 of 42	12 of 46	88	NCT03572049	Trial comparisons
SUBA Itraconazole vs Conventional Itraconazole: Resolution of Signs and Symptoms of Invasive Fungal Infection on Day 42	29 of 37	30 of 40	77	NCT03572049	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38440302	DERIVED	1	PubMed
32457106	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018312

GET https://conductscience.org/api/diseases/v1/MONDO_0018312/drugs

API reference For AI assistants